Protalix Change In Cash from 2010 to 2026

PLX Stock  USD 2.08  0.01  0.48%   
Protalix Biotherapeutics Change In Cash yearly trend continues to be fairly stable with very little volatility. Change In Cash is likely to outpace its year average in 2026. During the period from 2010 to 2026, Protalix Biotherapeutics Change In Cash regression line of annual values had r-squared of  0.03 and arithmetic mean of (1,308,881). View All Fundamentals
 
Change In Cash  
First Reported
1996-09-30
Previous Quarter
-1.6 M
Current Value
-4.2 M
Quarterly Volatility
12.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.2 M, Selling General Administrative of 49.3 M or Other Operating Expenses of 32.3 M, as well as many indicators such as Price To Sales Ratio of 2.79, Dividend Yield of 0.0 or PTB Ratio of 3.45. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Protalix Stock
Check out the analysis of Protalix Biotherapeutics Correlation against competitors.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Latest Protalix Biotherapeutics' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Protalix Biotherapeutics over the last few years. It is Protalix Biotherapeutics' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Pretty Stable
   Change In Cash   
       Timeline  

Protalix Change In Cash Regression Statistics

Arithmetic Mean(1,308,881)
Geometric Mean8,709,627
Coefficient Of Variation(1,379)
Mean Deviation13,949,418
Median(3,486,600)
Standard Deviation18,047,522
Sample Variance325.7T
Range66M
R-Value(0.17)
Mean Square Error337.1T
R-Squared0.03
Significance0.51
Slope(615,592)
Total Sum of Squares5211.4T

Protalix Change In Cash History

2026-3.3 M
2025-3.5 M
2024-3.9 M
20236.5 M
2022-21.9 M
202120.7 M
2020473 K

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Change In Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Cash-3.5 M-3.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.